CytomX
104 employees on LinkedIn · 4 known investors
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
Founders & leadership
SA
Sean A. McCarthyinChief Executive Officer and ChairmanExecutive Officer, Director at CytomX Therapeutics
MP
Marcia P. BelvininSVP, Chief Scientific Officer
DB
Dawn BensoninSVP, Quality and Product Manufacturing
WC
Wayne ChuChief Medical Officer
RL
Rachael LesterinSVP, Chief Business Officer
CO
Chris OgdeninChief Financial Officer
LR
Leslie RobbinsinSVP, Intellectual Property
SR
Stephanie RobertsoninSVP, Alliances & Program Leadership
DO
Danielle Olander-MoghadassianinConsulting Chief Human Resources Officer
LA
Lloyd A. Rowland, Jr.Consulting General Counsel
MG
Mamata GokhaleSVP, Regulatory Affairs
AC
Alejandra CarvajalChief Legal Officer
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountequity offeringMar 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through CytomX went on to found or lead other companies.
In the news
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026
CytomX Therapeutics (CTMX) posts Q2 loss, expands Regeneron cancer pactstocktitan.net · Aug 2026
CytomX Q2 Results: $37M Regeneron Payment, $330M Cash | CTMX Stock Newsstocktitan.net · Aug 2026
CytomX Therapeutics (NASDAQ: CTMX) swings to Q2 loss, adds $37M Regeneron feestocktitan.net · Aug 2026Frequently asked questions
- What does CytomX do?
- CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
- Who are CytomX's investors?
- CytomX's investors include Canaan Partners, Longitude Capital, Pfizer Venture Investments, OrbiMed.